Results 41 to 50 of about 21,457 (213)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Arthritis Research & Therapy, 2018
Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE ...
Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A. Ahmad, Philip J. Mease   +6 more
doaj   +1 more source

Effects of CTLA4-Ig on human monocytes

Inflammation and Regeneration, 2017
Background Abatacept, a CTLA4-Ig fusion protein attenuates T cell activation by inhibiting the CD80/86-CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid ...
Toshihiro Tono, Satoko Aihara, Takayuki Hoshiyama, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata   +5 more
doaj   +1 more source

Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial [PDF]

, 2016
Objective: To clarify the efficacy and safety of abatacept for secondary Sjögren’s syndrome (SS) associated with rheumatoid arthritis (RA).Methods: The primary endpoint of this open-labeled, prospective, observational multicenter study for secondary SS ...
Asashima Hiromitsu, Ebe Hiroshi, Hagiwara Shinya, Hirata Shintaro, Hirota Tomoya, Honda Fumika, Horai Yoshiro, Kawakami Atsushi, Kondo Yuya, Kurata Izumi, Matsumoto Isao, Miki Haruka, Nakamura Hideki, Ohyama Ayako, Saito Kazuyoshi, Sumida Takayuki, Takahashi Hidenori, Takahashi Hiroyuki, Tanaka Yoshiya, Tsuboi Hiroto, Umeda Naoto, Yagishita Mizuki, Yokosawa Masahiro, 三木 春香, 住田 孝之, 坪井 洋人, 松本 功, 浅島 弘充, 髙橋 広行   +28 more
core   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT

Scientific Reports
This exploratory study aimed to examine the impact of abatacept treatment on bone structure in patients with rheumatoid arthritis (RA) using high-resolution peripheral quantitative computed tomography (HR-pQCT). RA patients initiating either abatacept or
Naoki Iwamoto, Ko Chiba, Shuntaro Sato, Shigeki Tashiro, Kazuteru Shiraishi, Kounosuke Watanabe, Nozomi Ohki, Akitomo Okada, Tomohiro Koga, Shin-ya Kawashiri, Mami Tamai, Makoto Osaki, Atsushi Kawakami   +12 more
doaj   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

Arthritis Care &Research, EarlyView.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker, Yangyuna Yang, Punyasha Roul, Aaron Baraff, Myra S. Schmaderer, Lani Zimmerman, Kaleb Michaud, Namrata Singh, Grant W. Cannon, Gary Kunkel, Ted R. Mikuls, Ariela R. Orkaby, Joshua F. Baker, Bryant R. England, Katherine D. Wysham   +14 more
wiley   +1 more source

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

BMC Rheumatology, 2021
Background Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes chronic synovitis, resulting in progressive joint destruction and functional disability and affects approximately 400,000 people in the UK. This real-world study aimed
Ernest Choy, Lara Groves, Daniel Sugrue, Michael Hurst, John Houghton, Srinivasan Venkatachalam, Yusuf I. Patel, James R. Maxwell, Kevin G. Pollock, Sadie Henning   +9 more
doaj   +1 more source

Detection of treatment effects by covariate-adjusted expected shortfall

, 2011
The statistical tests that are commonly used for detecting mean or median treatment effects suffer from low power when the two distribution functions differ only in the upper (or lower) tail, as in the assessment of the Total Sharp Score (TSS) under ...
He, Xuming, Hsu, Ya-Hui, Hu, Mingxiu
core   +1 more source

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis [PDF]

, 2016
Objectives: To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving ...
Baker, Bernard G Combe, Charles Peterfy, Conaghan, Conaghan, Daniel E Furst, Dennis A Wong, Detert, Emery, Emery, Emery, Gandjbakhch, Gerd R Burmester, Herrero-Beaumont, Hetland, Julie C DiCarlo, Lenschow, McQueen, McQueen, Mease, Paul Emery, Peterfy, Peterfy, Peterfy, Philip G Conaghan, Quinn, Smolen, Tom W J Huizinga, Vivian P Bykerk, Østergaard   +29 more
core   +3 more sources

Clinical, histological, and serological predictors of renal function loss in lupus nephritis.

Arthritis Care &Research, Accepted Article.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang, Laurence Magder, Daniel Goldman, Judith A. James, Joel M Guthridge, Carla Guthridge, Peter Izmirly, Jill P Buyon, H.Michael Belmont, Richard A. Furie, Noa Schwartz, Chaim Putterman, Jennifer L. Barnas, Jennifer H. Anolik, Sarah French, Maria Dall'era, Avi Z. Rosenberg, Jeffrey Hodgin, Dawit S. Demeke, the Accelerating Medicines Partnership RA/SLE Network, Michelle Petri, Andrea Fava   +21 more
wiley   +1 more source